Celgene Corp (NASDAQ:CELG)

CAPS Rating: 5 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Results 1 - 20 of 262 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar TygerSpark (44.56) Submitted: 1/29/2016 2:42:49 PM : Outperform Start Price: $98.57 CELG Score: +6.25

I don't think you would go wrong with Celgene or Gilead. I like the future prospects of both.

Recs

0
Member Avatar 1russianguy (< 20) Submitted: 1/19/2016 12:38:31 PM : Outperform Start Price: $118.64 CELG Score: -5.46

SBD2016

Recs

0
Member Avatar KEBowman (33.29) Submitted: 1/18/2016 6:07:15 PM : Outperform Start Price: $102.51 CELG Score: +0.26

Another biotech superstar

Recs

0
Member Avatar gwolford (40.89) Submitted: 1/14/2016 5:12:27 PM : Outperform Start Price: $101.95 CELG Score: -0.22

great pipeline; Revlimid market leader

Recs

0
Member Avatar DBMcNC (53.43) Submitted: 1/7/2016 5:57:01 PM : Outperform Start Price: $112.82 CELG Score: -5.41

New technology which will succeed.

Recs

0
Member Avatar roymarshall (24.02) Submitted: 11/12/2015 5:06:26 PM : Outperform Start Price: $109.02 CELG Score: +1.87

bought this last month at 108 and sold at 128. Bought back today 111 and will ladder down for a bounce into ye.

Recs

0
Member Avatar onlyonewoof (< 20) Submitted: 10/25/2015 2:01:06 PM : Outperform Start Price: $120.31 CELG Score: -5.43

Celgene has tremendous legs and extremely deep R/D with over 13 drugs in the pipeline of FDA trials. Despite emotional responses from recent fears over drug pricing, recent purchases including Juno will allow this to outperform in both the near and long term.

Recs

0
Member Avatar drapca (44.25) Submitted: 9/29/2015 1:18:09 AM : Outperform Start Price: $120.00 CELG Score: -10.33

Aging baby boomer population that lives longer will drive need for product. Company is doing right things with R&D as well as careful acquisition. Bought stock, plan to hold.

Recs

0
Member Avatar wkdkdka84 (< 20) Submitted: 9/28/2015 3:13:34 PM : Outperform Start Price: $105.34 CELG Score: -2.65

Will outperform

Recs

0
Member Avatar justinr (65.84) Submitted: 9/5/2015 4:59:20 AM : Outperform Start Price: $120.00 CELG Score: -10.33

Top biotech pick

Recs

0
Member Avatar CMFMLove (< 20) Submitted: 9/3/2015 4:01:06 PM : Outperform Start Price: $115.88 CELG Score: -8.88

Celgene trades at more than 2x premium P/E relative to the large-cap biotech group (44.6 compared to around 21.6). Is it worth it? Yes. High income drugs, a deep pipeline and prudent acquisitions make Celgene a premium company to own for the long-term. Buying on the dip.

Recs

0
Member Avatar iksnamyzs (62.35) Submitted: 8/20/2015 5:02:25 PM : Outperform Start Price: $122.81 CELG Score: -9.55

good pipeline

Recs

0
Member Avatar optioncoach (84.74) Submitted: 8/18/2015 2:36:39 PM : Outperform Start Price: $129.82 CELG Score: -10.35

Putting some long biotech back in the portfolio.

Recs

0
Member Avatar CellBlock9 (89.96) Submitted: 8/17/2015 9:49:10 PM : Outperform Start Price: $131.50 CELG Score: -11.23

mgk

Recs

0
Member Avatar LifeForceDancr (21.94) Submitted: 8/17/2015 8:21:32 PM : Outperform Start Price: $131.50 CELG Score: -11.23

Biotech

Recs

0
Member Avatar Herbstmd (36.62) Submitted: 8/8/2015 8:16:13 PM : Outperform Start Price: $129.85 CELG Score: -10.68

More older folks in the baby boomers, more cancer on the way, more money tonight and treat cancer. Celgene has a great expanding market.

Recs

0
Member Avatar TMFInnovator (20.11) Submitted: 8/7/2015 4:27:20 PM : Outperform Start Price: $129.85 CELG Score: -10.68

CELG has done an excellent job in developing partnerships for early-stage cancer immunotherapy treatments.

This will take years to develop. But I expect patient shareholders to be rewarded.

Recs

0
Member Avatar dstwhit (24.78) Submitted: 7/10/2015 2:45:45 PM : Outperform Start Price: $119.14 CELG Score: -4.42

top dog w/wide moat; innovative company and deals with other medical companies (e.g., JUNO); glassdoor rating; rb; linde; growing industry working to improve health; reasonable risk rating.

Recs

0
Member Avatar nevercontent (86.95) Submitted: 4/30/2015 12:17:04 PM : Outperform Start Price: $109.02 CELG Score: +4.18

management predicted that the company would see 18% compound annual sales growth through 2020 (15% based on existing drugs) and 23% compound annual EPS growth to $12.50/share. At a subsequent analyst presentation, the CFO did a lot of nodding and winking about how conservative those estimates might be. Even allowing for P/E compression from the current 47 to, say, a P/E of 20 come 2020, $12.50 EPS would imply a share price of over $250, more than double today’s ~$110. That’s a compound annual return rate approaching 18%/year — with optionality to the upside, as management would say.

But the market looks ahead, of course. 5 years from now, the price won’t be based on Celgene’s past revenues but the company’s future opportunities as the patents on its current stable of drugs come to an end. There are probably slightly higher barriers to entry for Revlimid and Pomalyst/Imnovid as generics companies not only need to duplicate the compound but also a risk-management program that the FDA finds credible. But generally speaking, the question remain the same: will Celgene be able to turn its current pipeline into significant future opportunity and continue to fuel growth?

Recs

0
Member Avatar artemous (48.08) Submitted: 4/1/2015 5:49:57 PM : Outperform Start Price: $114.09 CELG Score: -1.55

Its cutting edge

Featured Broker Partners